克罗恩病中抗 FcϵRI 自身抗体的患病率和临床意义
IF 3.7
3区 医学
Q2 ALLERGY
引用次数: 0
摘要
背景：肥大细胞可通过各种方式被激活，并被证明与克罗恩病（CD）的发病有关。克罗恩病的诊断仍然具有挑战性，寻找新型生物标记物是一项值得努力的工作：方法：利用涂有人 Fc&epsivRIα 的微孔板和酶标记的抗人 IgG 作为二抗，成功建立了一种间接酶联免疫吸附试验（ELISA），用于半定量检测血清中的 IgG 抗 Fc&epsivRI。探索了最佳工作条件，随后进行了方法评估。收集了 117 名 CD 患者和 75 名健康对照者的血清样本和临床数据。IgE 采用浊度法测定；IgG 抗 IgE 和 IgG 抗 Fc&epsivRI 采用 ELISA 法检测。IgG抗胰腺抗体（PAB）和抗酿酒酵母抗体（ASCA）通过间接免疫荧光法测定。对临床特征进行了数据分析：IgG抗Fc&epsivRI是CD的有效标记物（P <0.001），但IgE和IgG抗IgE（P = 0.089，0.219）不是。抗 IgE 与抗 Fc&epsivRI 呈正相关（R = 0.380，P <0.001）。抗 Fc&epsivRI 阳性患者的疾病活动度更高[OR：1.478（1.200~1.821），P <0.001]，但在蒙特利尔分类中位于 L4 的可能性较低[OR：0.253（0.077~0.837），P = 0.024]。现有指标 PAB 和 ASCA 的特异性较高（均为 95%），而敏感性较低（均为 30%）。抗-Fc&epsivRI与现有指标的结合大大提高了诊断效率[AUC：0.879（0.831~0.928）]：结论：建立并验证了一种检测抗Fc&epsivRI的酶联免疫吸附试验，这可能有助于促进对克罗恩病的研究。抗Fc&epsivRI阳性的克罗恩病患者的疾病活动指数较高，这表明它在克罗恩病的诊断和治疗中具有潜在价值。本文章由计算机程序翻译，如有差异，请以英文原文为准。
Prevalence and Clinical Relevance of Anti-FcϵRI Autoantibody in Crohn’s Disease
Background: Mast cells can be activated in various ways and were shown to be involved in the development of Crohn’s disease (CD). The diagnosis of CD is still challenging, and seeking novel biomarkers is a worthwhile endeavor.
Methods: An indirect enzyme-linked immunosorbent assay (ELISA) was successfully established for semi-quantitative detection of IgG anti-Fc&epsivRI in serum using human Fc&epsivRIα coated microplates and an enzyme-labeled anti-human IgG as secondary antibodies. The optimal working conditions were explored, followed by conducting the method evaluation. The serum samples and clinical data of 117 CD patients and 75 healthy controls were collected. IgE was measured by the rate turbidity turbidimetry; IgG anti-IgE and IgG anti-Fc&epsivRI were detected by ELISA. IgG anti-pancreatic antibody (PAB) and anti-Saccharomyces cerevisiae antibody (ASCA) were determined by indirect immunofluorescence assay. Data were analyzed concerning the clinical characteristics.
Results: IgG anti-Fc&epsivRI was an effective marker for CD (P < 0.001), but IgE and IgG anti-IgE (P = 0.089, 0.219, respectively) were not. There was a positive correlation between anti-IgE and anti-Fc&epsivRI (R = 0.380, P < 0.001). Anti-Fc&epsivRI positive patients behaved with higher disease activity [OR: 1.478 (1.200~1.821), P < 0.001], but were less likely to be located in L4 among Montreal classification [OR: 0.253 (0.077~0.837), P = 0.024]. Existing indicators, PAB and ASCA, behaved with high specificity (both > 95%) with low sensitivity (both < 30%). The combination of anti-Fc&epsivRI with existing markers significantly improved the diagnostic efficiency [AUC: 0.879 (0.831~0.928)].
Conclusion: An ELISA for the detection of anti-Fc&epsivRI was established and validated, which may contribute to facilitating research on Crohn’s diseases. Anti-Fc&epsivRI positive CD patients were associated with higher disease activity indices, suggesting its potential value in the diagnosis and management of CD.
Methods: An indirect enzyme-linked immunosorbent assay (ELISA) was successfully established for semi-quantitative detection of IgG anti-Fc&epsivRI in serum using human Fc&epsivRIα coated microplates and an enzyme-labeled anti-human IgG as secondary antibodies. The optimal working conditions were explored, followed by conducting the method evaluation. The serum samples and clinical data of 117 CD patients and 75 healthy controls were collected. IgE was measured by the rate turbidity turbidimetry; IgG anti-IgE and IgG anti-Fc&epsivRI were detected by ELISA. IgG anti-pancreatic antibody (PAB) and anti-Saccharomyces cerevisiae antibody (ASCA) were determined by indirect immunofluorescence assay. Data were analyzed concerning the clinical characteristics.
Results: IgG anti-Fc&epsivRI was an effective marker for CD (P < 0.001), but IgE and IgG anti-IgE (P = 0.089, 0.219, respectively) were not. There was a positive correlation between anti-IgE and anti-Fc&epsivRI (R = 0.380, P < 0.001). Anti-Fc&epsivRI positive patients behaved with higher disease activity [OR: 1.478 (1.200~1.821), P < 0.001], but were less likely to be located in L4 among Montreal classification [OR: 0.253 (0.077~0.837), P = 0.024]. Existing indicators, PAB and ASCA, behaved with high specificity (both > 95%) with low sensitivity (both < 30%). The combination of anti-Fc&epsivRI with existing markers significantly improved the diagnostic efficiency [AUC: 0.879 (0.831~0.928)].
Conclusion: An ELISA for the detection of anti-Fc&epsivRI was established and validated, which may contribute to facilitating research on Crohn’s diseases. Anti-Fc&epsivRI positive CD patients were associated with higher disease activity indices, suggesting its potential value in the diagnosis and management of CD.
求助全文
通过发布文献求助，成功后即可免费获取论文全文。
去求助
来源期刊
Journal of Asthma and Allergy
Medicine-Immunology and Allergy
CiteScore
5.30
自引率
6.20%
发文量
185
审稿时长
16 weeks
期刊介绍：
An international, peer-reviewed journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies.
Although the main focus of the journal will be to publish research and clinical results in humans, preclinical, animal and in vitro studies will be published where they shed light on disease processes and potential new therapies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
